Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials
Abstract The efficacy and safety of Hydroxychloroquine (HCQ) in treating coronavirus disease (COVID-19) is disputed. This systematic review and meta-analysis aimed to examine the efficacy and safety of HCQ in addition to standard of care (SOC) in COVID-19. PubMed, the Cochrane Library, Embase, Web o...
Guardado en:
Autores principales: | Bahman Amani, Ahmad Khanijahani, Behnam Amani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3fae3b80e5fa43b392327e3396b82de0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
por: Behnam Amani, et al.
Publicado: (2021) -
A Standard of Care
por: Peter M. Bingham
Publicado: (2017) -
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
por: Cathrine Axfors, et al.
Publicado: (2021) -
Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements?
por: Timothée Olivier, et al.
Publicado: (2022) -
Social-skills and parental training plus standard treatment versus standard treatment for children with ADHD--the randomised SOSTRA trial.
por: Ole Jakob Storebø, et al.
Publicado: (2012)